Suppr超能文献

[经动脉化疗和免疫治疗的肝细胞癌长期生存病例]

[A long-survival case of hepatocellular carcinoma treated by intra-arterial chemotherapy and immunotherapy].

作者信息

Nagano H, Sasaki Y, Imaoka S, Shibata T, Wada H, Ishikawa O, Ohigashi H, Kabuto T, Hurukawa H, Fukuda I

机构信息

Dept. of Surgery, Center for Adult Diseases.

出版信息

Gan To Kagaku Ryoho. 1989 Aug;16(8 Pt 2):2961-4.

PMID:2551235
Abstract

Hepatic resection is generally considered to be superior to any other therapeutic procedures for hepatocellular carcinoma (H.C.C.). However, the resectability of the patients who have HCC. with liver cirrhosis is still low, and surgery is appropriate in only a minority of patients. Although some successful reports of intra-arterial chemotherapy for HCC. have been documented, most of the therapeutic effects are transient and the survival rate is not satisfactory. This report is of a rare case, that of a long-term survivor with HCC treated by intra-arterial chemotherapy and immunotherapy. A 66-year-old man, with a 10-year history of liver cirrhosis was admitted to The Center for Adult Diseases, Osaka, after detection of a tumor in the right lobe on US. On admission, serum AFP was within normal range, HBs-Ag was negative, and ICG-R 15 was 20.8%. On hepatic angiogram, a hypervascular tumor (6 cm in size) was recognized in the middle of the right lobe. He was assessed as unresectable because of insufficient reserve capacity, and the catheterization of the hepatic artery for intra-arterial chemotherapy and the injection 35 KE of OK-432 into the tumor were carried out under laparotomy. After the procedure, the patient was treated by intra-arterial infusion of doxorubicin (ADR) at a total dose of 150 mg and 5-FU in total dose of 25 g, with a hypodermic injection of OK-432 at a total dose of 161 KE. Hepatic angiography, carried out one year after the procedure, disclosed no foci in the liver. The duration of complete remission continued more than 5 years. The patient eventually died of intrahepatic recurrence, but he lived for 7 years and 3 months after the catheterization.

摘要

肝切除术通常被认为是治疗肝细胞癌(HCC)的最佳治疗方法。然而,伴有肝硬化的HCC患者的可切除性仍然很低,只有少数患者适合手术治疗。虽然已有一些关于HCC动脉内化疗成功的报道,但大多数治疗效果是暂时的,生存率并不理想。本报告是一例罕见病例,即通过动脉内化疗和免疫治疗的HCC长期存活者。一名66岁男性,有10年肝硬化病史,因超声检查发现右叶肿瘤而入住大阪成人疾病中心。入院时,血清甲胎蛋白在正常范围内,乙肝表面抗原阴性,吲哚氰绿滞留率(ICG-R 15)为20.8%。肝血管造影显示右叶中部有一个高血运肿瘤(大小为6厘米)。由于储备功能不足,他被评估为不可切除,并在剖腹手术中进行了肝动脉插管以进行动脉内化疗,并向肿瘤内注射35KE的溶链菌制剂(OK-432)。术后,患者接受动脉内输注阿霉素(ADR),总剂量为150毫克,氟尿嘧啶(5-FU)总剂量为25克,并皮下注射OK-432,总剂量为161KE。术后一年进行的肝血管造影显示肝脏内无病灶。完全缓解持续时间超过5年。患者最终死于肝内复发,但在插管后存活了7年零3个月。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验